217 related articles for article (PubMed ID: 33810909)
1. Does incarceration influence patients' goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail.
Vail W; Faro E; Watnick D; Giftos J; Fox AD
Drug Alcohol Depend; 2021 May; 222():108529. PubMed ID: 33810909
[TBL] [Abstract][Full Text] [Related]
2. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
3. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
[TBL] [Abstract][Full Text] [Related]
4. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
5. Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration.
Cherian T; Lim S; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Rosner Z; MacDonald R; Lee JD
Drug Alcohol Depend; 2024 Jun; 259():111274. PubMed ID: 38643529
[TBL] [Abstract][Full Text] [Related]
6. "Just fighting for my life to stay alive": a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories.
Hoffman KA; Thompson E; Gaeta Gazzola M; Oberleitner LMS; Eller A; Madden LM; Marcus R; Oberleitner DE; Beitel M; Barry DT
Addict Sci Clin Pract; 2023 Mar; 18(1):16. PubMed ID: 36944998
[TBL] [Abstract][Full Text] [Related]
7. Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study.
Cheng A; Badolato R; Segoshi A; McDonald R; Malone M; Vasudevan K; Badiei B; Sugarman A; Macdonald R; Mangat J; Giftos J; Lee JD; Tofighi B
Addict Sci Clin Pract; 2022 Jan; 17(1):4. PubMed ID: 35093164
[TBL] [Abstract][Full Text] [Related]
8. United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder.
Benck KN; Seide K; Jones AK; Omori M; Rubinstein LB; Beckwith C; Nowotny KM
Drug Alcohol Depend; 2023 Jun; 247():109863. PubMed ID: 37071946
[TBL] [Abstract][Full Text] [Related]
9. Use of non-prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration.
Gryczynski J; Lee JD; Dusek K; McDonald R; Sharma A; Malone M; Monico LB; Cheng A; DeVeaugh-Geiss A; Chilcoat HD
J Subst Abuse Treat; 2021 Aug; 127():108349. PubMed ID: 34134866
[TBL] [Abstract][Full Text] [Related]
10. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
[TBL] [Abstract][Full Text] [Related]
11. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.
Lee JD; Malone M; McDonald R; Cheng A; Vasudevan K; Tofighi B; Garment A; Porter B; Goldfeld KS; Matteo M; Mangat J; Katyal M; Giftos J; MacDonald R
JAMA Netw Open; 2021 Sep; 4(9):e2123032. PubMed ID: 34495340
[TBL] [Abstract][Full Text] [Related]
13. Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration.
Monico LB; Gryczynski J; Lee JD; Dusek K; McDonald R; Malone M; Sharma A; Cheng A; DeVeaugh-Geiss A; Chilcoat H
J Subst Abuse Treat; 2021 Apr; 123():108267. PubMed ID: 33612198
[TBL] [Abstract][Full Text] [Related]
14. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder.
Evans EA; Wilson D; Friedmann PD
Drug Alcohol Depend; 2022 Feb; 231():109254. PubMed ID: 35063323
[TBL] [Abstract][Full Text] [Related]
15. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
16. "I Kicked the Hard Way. I Got Incarcerated." Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments.
Maradiaga JA; Nahvi S; Cunningham CO; Sanchez J; Fox AD
J Subst Abuse Treat; 2016 Mar; 62():49-54. PubMed ID: 26747509
[TBL] [Abstract][Full Text] [Related]
17. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.
Stopka TJ; Rottapel RE; Ferguson WJ; Pivovarova E; Toro-Mejias LD; Friedmann PD; Evans EA
Int J Drug Policy; 2022 Dec; 110():103803. PubMed ID: 35965159
[TBL] [Abstract][Full Text] [Related]
18. "And Then COVID Hits": A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19.
Harrington C; Bailey A; Delorme E; Hano S; Evans EA
Subst Use Misuse; 2023; 58(2):266-274. PubMed ID: 36510800
[No Abstract] [Full Text] [Related]
19. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
Treitler PC; Enich M; Reeves D; Crystal S
Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
[No Abstract] [Full Text] [Related]
20. Developing a cascade of care for opioid use disorder among individuals in jail.
Ray B; Victor G; Cason R; Hamameh N; Kubiak S; Zettner C; Dunnigan M; Comartin E; Costello M
J Subst Abuse Treat; 2022 Jul; 138():108751. PubMed ID: 35241352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
